All News

RA ILD RTX lung

Rituximab vs. JAK inhibitors in Rheumatoid Lung Disease

d Jack Cush, MD

There are no current FDA approved therapies for rheumatoid arthritis associated interstitial lung disease (RA-ILD) or bronchiectasis, but a recent retrospective cohort study showed equivalent outcomes when RA-ILD patients were treated with either rituximab or janus kinase inhibitors.

Read Article
RheumNow Podcast square

RheumNow Podcast – Great Associations (3.19.2021)

d Jack Cush, MD

Dr. Jack Cush rants on the journal reports, news and FDA actions featured this past week on RheumNow.com.

Read Article
Super RA superman

Are You a Super Rheum?

d Jack Cush, MD

Several weeks ago, at the Rheumatology Winter Clinical Symposia, an interesting debate between Drs. Orrin Troum and Marty Bergman hashed over the concept of whether rheumatologists should sub-specialize with a practice, research or career devoted to one disease ("Super Rheum"), or be "selective" about what disorders and diseases they would treat or just be a generalist. 

Read Article
hudsonpsoriasis.jpg

Apremilast Equals MTX in Palmoplantar Psoriasis

d Jack Cush, MD

Palmoplantar psoriasis (PPP) is a therapeutically challenging variant of psoriasis; nonetheless, a prospective, randomized, active-controlled trial from India suggests that apremilast is effective and safe in patients with PPP.

Read Article
@RheumNow #RNL2021 Dr. Buttgereit on steroids in RA: 2.5 mg/d of prednisone increase total steroid amount in the body by 100% - great therapeutic effect but comes w/plethora of side effects. Q: how do you feel out long term low dose steroids for RA?

Olga Petryna DrPetryna ( View Tweet)

Follow the hashtag #RNL2021 for all RheumNow Live coverage today and tomorrow!

Dr. John Cush RheumNow ( View Tweet)

RheumNow Live has started! #RNL2021 https://t.co/CrNqnnKqUy
Dr. John Cush RheumNow ( View Tweet)
Metanalysis reveals significant heterogeneity in defining Refractory Disease in RA and polyarticular JIA. Should include: 1) Resistance to multiple drugs w/ different MOAs (≥2bDMARDs) and 2) Persistent symptoms and disease activity https://t.co/CL6Mr3cs7J

Links:

Dr. John Cush RheumNow ( View Tweet)

News Feature: Are You a Super Rheum? https://t.co/LsGpFNXlkp https://t.co/Q9iojEQNqL

Links:

Dr. John Cush RheumNow ( View Tweet)
Top 4 arthritis types that significantly increase the risk of CVA: 1) RA (RR=1.38), 2) ankylosing spondylitis (RR=1.49), 3) psoriatic arthritis (RR=1.33) & gout (RR=1.4). With these, the risk was higher in younger (<45 yrs) (RR = 1.46), not older (>65) https://t.co/Snb6OrtZJH

Links:

Dr. John Cush RheumNow ( View Tweet)

NAFLD, NASH and Risks with DMARDs and MTX https://t.co/LYV9WycEjz https://t.co/Vx0jvhjCsd

Links:

Dr. John Cush RheumNow ( View Tweet)
Kiniksa announced Arcalyst (rilonacept) has been FDA-approved for the treatment of recurrent pericarditis. Rilonacept, an IL-1 inhibitor, also FDA approved for CAPS (Cryopyrin-Assoc Periodic Syndr) & DIRA (Defic IL-1 Recept Antag) https://t.co/erpiyuhsAv https://t.co/xp764WkWEI

Links:

Dr. John Cush RheumNow ( View Tweet)

News Feature: MDA-5 Antibodies and Juvenile Dermatomyositis https://t.co/vxyXZyO0gs https://t.co/GgzhnhlmdR

Links:

Dr. John Cush RheumNow ( View Tweet)
SPIRIT‐P3 RCT treated biologic‐naive PsA with ixekizumab x36 wks; those w/ MDA x 3 mos were randomized to continue or withdraw IXE (blinded). There were significantly more relapses when IXE was stopped; most regained control when started https://t.co/lhQ8X1Ef48

Links:

Dr. John Cush RheumNow ( View Tweet)

RCT shows Stepped Exercise Program to be effective in Knee Osteoarthritis. VAMC study of 345 knee OA pts given either STEP-KOA (internet based progr) or an arthritis education (control). WOMAC scores at 9 mos were 6.8 points lower in the STEP-KOA group.https://t.co/EuoPyJkTif

Links:

Dr. John Cush RheumNow ( View Tweet)

There's still time to sign up. Attend RheumNow Live this weekend. We have a robust schedule planned with top professional. https://t.co/LJ3qClHTKh

Links:

Dr. John Cush RheumNow ( View Tweet)

Hydroxychloroquine studied vs Vitamin C (PBO) prophylaxis to households (n=671) exposed to COVID-19. 89% were COVD1-9 test neg at baseline. HCQ did not protect against progression to COVID (53 vs 45 events; adj HR, 1.10 [95% CI, 0.73 to 1.66]. A vit C Win! https://t.co/S5qjdIYaXq

Links:

Dr. John Cush RheumNow ( View Tweet)

The Reflecting Rheum: Top Publications from 2020 Covering SpA and Still’s Disease Sponsored by Novartis Medical Affairs Listen to a panel of experts share their views on top spondyloarthritis and Still’s disease publications from 2020. View Now: https://t.co/rxTAwQNalx https://t.co/y8wnHSmBug

Links:

Dr. John Cush RheumNow ( View Tweet)
Phase III RCT of apremilast showed no benefit in ankylosing spondylitis pts. 490 AS pts recv placebo or apremilast 20 mg or 30 mg bid 24 wks. The ASAS 20 was the same in all groups (PBO: 37%; 20 mg 35%; 30 mg 33). 2 yrs Xray changes were equal too. https://t.co/ILYtVMZp80

Links:

Dr. John Cush RheumNow ( View Tweet)

Concise overview of Ehlers-Danlos syndrome from Medscape...FYI https://t.co/acHSoEhVVF

Links:

Dr. John Cush RheumNow ( View Tweet)

×